COG Sessions

3:30 – 4:30 pm Wednesday, September 2

Less is More in Childhood B-ALL: Targeted immunotherapies, MRD by HTS, and De-escalation of Therapy in COG Trials AALL1731/AALL1732 (C210)

coglogoWhile survival rates in childhood B-lymphoblastic leukemia (B-ALL) have improved significantly, relapse among this population is still common, and for relapsed patients, 5-year overall survival (OS) is approximately 38%. Interventions that reduce B-ALL relapses remain a priority as an intensification of conventional chemotherapy has proven unsuccessful.

Read more...
Speaker:
Sue Zupanec, MN NP
Christine Yun, MSN PNP CPON®
CNE Hours
1
12:15 – 1:15 pm Thursday, September 3

Cancer Control and Supportive Care in the Children’s Oncology Group: Nursing Roles and Recent Results (C215)

coglogoSurvival rates for many pediatric cancers have improved over time, although children and adolescents continue to experience acute and delayed toxicities related to their disease and treatment. This session will review the purpose and research domains within the Children’s Oncology Group (COG) Cancer Control (CCL) Committee.

Read more...
Speaker:
Jessica Ward, PhD MPH RN CPNP
Melissa Beauchemin, PhD RN CPNP CPON®
CNE Hours
1
2:30 – 3:30 pm Thursday, September 3

Reproductive Health: from Diagnosis through Survivorship – Resources and Perspectives from the Children’s Oncology Group (C221)

coglogoPuberty and sexual and reproductive health are normal parts of human growth and development. Adolescence and young adulthood are developmental times of exploration of sexual identity and planning for the future, which may include parenting goals. A cancer diagnosis does not preclude a patient or their family from concern about sexual and reproductive health.

Read more...
Speaker:
Brooke Cherven, PhD MPH RN CPON®
Barbara Lockart, DNP APRN PC & AC CPHON®
CNE Hours
1
12:15 – 1:15 pm Friday, September 4

High Risk Neuroblastoma in the new decade: Incorporating targeted therapies to maximize impact in current Children’s Oncology Group trials (C226)

coglogoWhile the overall cure rate for childhood cancer is approaching 80%, the prognosis for long-term survival for children with high risk neuroblastoma lags considerably behind, at 50%–60%. Upfront standard treatment for high-risk neuroblastoma protocols within the Children’s Oncology Group (COG) has historically utilized all available modalities of cancer treatment including chemotherapy, surgery, myeloablative chemotherapy with stem cell rescue, radiation therapy, differentiating agents, and most recently biologic therapy with anti-GD2 antibody (dinutuximab) used post consolidation in ANBL0032.

Read more...
Speaker:

Wendy Fitzgerald, MSN APRN PPCNP-BC

Denise Mills, MN RN(EC) NP CPHON®

CNE Hours
1
2:30 – 3:30 pm Friday, September 4

How to Return Research Results to Patients and Families? The Children’s Oncology Group Experience (C232)

coglogoIn North America, the majority of children with cancer will enroll in a clinical trial at some point during their treatment. Clinical research is rooted in the premise that the quantity and quality of human lives will be improved by carefully conducted clinical and basic research.

Read more...
Speaker:
Kimberly Pyke-Grimm, PhD RN CNS CPHON®
CNE Hours
1